For the Inventor, By the Inventor

Enter assignee name

Monheim, Germany

Ucb Pharma Gmbh

Calculating rank

USPTO Granted Patents = 64

% Expired Patents = 53.1

CIPO Patents = 6

EPO Patents = 31

Trademarks = 7

Forward Citations = 210

Loading Chart...

Loading Chart...

87 inventors (with patents filed for the assignee):

Hans-Michael Wolff (14 out of 28 patents)

Claus Meese (9 out of 18 patents)

Christoph Arth (7 out of 12 patents)

4. Cécile Pegurier (6 out of 6 patents)

5. Thomas Stöhr (6 out of 7 patents)

6. Dieter Scheller (6 out of 6 patents)

7. Christa E Mueller (5 out of 5 patents)

8. Ali El-Tayeb (5 out of 6 patents)

9. Marie Ledecq (5 out of 5 patents)

10. Joerg Hockemeyer (5 out of 5 patents)

11. Thomas Stoehr (5 out of 7 patents)

12. Armin Breitenbach (5 out of 7 patents)

13. Luc Quere (5 out of 11 patents)

14. Laurent Provins (4 out of 16 patents)

15. Alain Merschaert (4 out of 4 patents)

Core Competencies:

CNS Disorders

GPR17 Modulators

Rotigotine

Anticonvulsant Therapy

Transdermal Delivery

Pharmaceutical Compositions

Pain Treatment

Lacosamide

Fesoterodine

Chiral Intermediates

Therapeutic Formulations

Parkinson's Disease

64 patents: Sort by Forward Citations

1. 12358875 - N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as GPR17 modulators for treating CNS disorders such as multiple sclerosis (2025-07-15),

2. 12071404 - Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides (2024-08-27),

3. 11976056 - Substituted alkoxypyridinyl indolsulfonamides (2024-05-07),

4. 11939319 - Pyridinyl and pyrazinyl-(asa)indolsulfonamides (2024-03-26),

5. 11820746 - Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides (2023-11-21),

6. 11345662 - Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides (2022-05-31),

7. 10350174 - Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine (2019-07-16),

8. 10149818 - Daily formulation of lacosamide (2018-12-11),

9. 10130589 - Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine (2018-11-20),

10. 9925150 - Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine (2018-03-27),

11. 9630908 - Process for preparing lacosamide (2017-04-25),

12. 9446011 - Anticonvulsant combination therapy (2016-09-20),

13. 9364541 - Pharmaceutical compositions comprising Fesoterodine (2016-06-14),

14. 9309215 - Chiral intermediate, process for producing the same and its use in the manufacture of tolterodine, fesoterodine, or the active metabolite thereof (2016-04-12),

15. 9308183 - Therapy for hyperexcitability disorders (2016-04-12),

Company Overview

Ucb Pharma GmbH, based in Monheim, Germany, specializes in the development and manufacturing of innovative therapies for central nervous system (CNS) disorders. The company focuses on advanced treatment options, including GPR17 modulators and transdermal delivery systems, aimed at improving patient outcomes in pain management and anticonvulsant therapy. Ucb Pharma is committed to addressing complex neurological conditions through its research in pharmaceutical compositions and targeted therapies, enhancing the quality of life for patients worldwide.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

64 Patents

#3 in Monheim

#877 in Germany

#11,485 in the World

Monheim, Germany

Ucb Pharma Gmbh

Forward Citations = 210

87 inventors:

Hans-Michael Wolff (14 out of 28 patents)

Claus Meese (9 out of 18 patents)

Christoph Arth (7 out of 12 patents)

4. Cécile Pegurier (6 out of 6 patents)

5. Thomas Stöhr (6 out of 7 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Ucb Pharma Gmbh. Retrieved from https://idiyas.com/company/ucb-pharma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…